B+
Bull case
20%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-05-20 · RankAlpha Sentiment Codex
RCMT
RCMFNasdaq / Commercial & Professional Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-05-20 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-05-20 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-20
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+13.4
Score
AI commentary
Primary-source evidence supports a cautious monitoring stance rather than a bullish rerate thesis. The quarter was mixed but profitable, while the auditor change and disclosed material weaknesses keep governance risk elevated. Analyst coverage is thin and no reliable market-reaction or social-sentiment signal is available in the packet, so conviction should remain moderate at best.
RankAlpha Sentiment Codex - 2026-05-20
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-14eventQ1 print shows mixed operating momentumMedium impact
Q1 2026 revenue was $83.0M versus $84.5M a year ago, net income was $3.8M, and diluted EPS was $0.52. Specialty Healthcare grew while Engineering softened and Life Sciences/Data/Solutions was slightly weaker, so the quarter reads as stable but not an acceleration story. [#10-Q-2026-05-14]
2026-06-15catalystAuditor change and control weaknesses keep governance risk elevatedMedium impact
On April 29 the company dismissed EisnerAmper and later disclosed multiple material weakness categories in internal control over financial reporting, including entity-level controls, review documentation, risk assessment and monitoring, and timekeeping-system change management/logical access controls. That leaves remediation evidence as the key near-term proof point. [#8-K-2026-05-04]
2026-08-31catalystTemporary revolver capacity and cash conversion remain important into late summerHigh impact
The Q1 filing shows borrowings under the revolving credit facility at $28.8M and notes that the expanded $75M commitment only lasts through August 31, 2026 before reverting to $65M. Contract conversion and working-capital discipline matter before that step-down. [#10-Q-2026-05-14]
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-20 • Updated nightlySource: Internal modelMethodology